Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer



Castration-resistant prostate cancer (CRPC) is the most common cause of death in men. The effectiveness of HDAC inhibitors has been demonstrated by preclinical models, but not in clinical studies, probably due to the ineffectively accumulation of HDACI in prostate cancer cells. The purpose of this work was to evaluate effects of a novel HDACI (CN133) on CRPC xenograft model and 22Rv1 cells, and develops methods, PET/CT imaging, to detect the therapeutic effects of CN133 on this cancer.


We designed and performed study to compare the effects of CN133 with SAHA on the 22Rv1 xenograft model and 22Rv1 cells. Using PET/CT imaging with [11C] Martinostat and [18F] FDG, we imaged mice bearing 22Rv1 xenografts before and after 21-day treatment with placebo and CN133 (1 mg/kg), and uptake on pre-treatment and post-treatment imaging was measured. The anti-tumor mechanisms of CN133 were investigated by qPCR, western blot, and ChIP-qPCR.


Our data showed that the CN133 treatment led to a 50% reduction of tumor volume compared to the placebo that was more efficacious than SAHA treatment in this preclinical model. [11C] Martinostat PET imaging could identify early lesions of prostate cancer and can also be used to monitor the therapeutic effect of CN133 in CRPC. Using pharmacological approaches, we demonstrated that effects of CN133 showed almost 100-fold efficacy than SAHA treatment in the experiment of cell proliferation, invasion, and migration. The anti-tumor mechanisms of CN133 were due to the inhibition of AR signaling pathway activity by decreased HDAC 2 and 3 protein expressions.


Taken together, these studies provide not only a novel epigenetic approach for prostate cancer therapy but also offering a potential tool, [11C] Martinostat PET/CT imaging, to detect the early phase of prostate cancer and monitor therapeutic effect of CN133. These results will likely lead to human trials in the future.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Data availability

Data transparency.



castration-resistance prostate cancer


histone deacetylase


histone deacetylase inhibitors


suberoylanilide hydroxamic acid


androgen receptor


chromatin immunoprecipitation


positron emission tomography




prostate specific antigen


recombinant Kallikrein 2


transmembrane protease serine 2


  1. 1.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014, (in eng). CA Cancer J Clin. 2014;64(1):9–29.

    Article  Google Scholar 

  2. 2.

    Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females, (in eng). CA Cancer J Clin. 2016;66(3):182–202.

    Article  Google Scholar 

  3. 3.

    Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer, (in eng). Semin Oncol. 2013;40(3):244–58.

    CAS  Article  Google Scholar 

  4. 4.

    Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer, (in eng). Prostate. 2004;59(2):177–89.

    CAS  Article  Google Scholar 

  5. 5.

    Weichert W, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy, (in eng). Br J Cancer. 2008;98(3):604–10.

    CAS  Article  Google Scholar 

  6. 6.

    Rathkopf DE, et al. A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer, (in eng). Cancer Chemother Pharmacol. 2013;72(3):537–44.

    CAS  Article  Google Scholar 

  7. 7.

    Molife LR, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC), (in eng). Ann Oncol. 2010;21(1):109–13.

    CAS  Article  Google Scholar 

  8. 8.

    Bradley D, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium, (in eng). Cancer. 2009;115(23):5541–9.

    CAS  Article  Google Scholar 

  9. 9.

    Liu Y, et al. A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer, (in eng). J Nucl Med. 2013;54(12):2132–8.

    CAS  Article  Google Scholar 

  10. 10.

    Huang CW, Li Z, Cai H, Chen K, Shahinian T, Conti PS. Design, synthesis and validation of integrin alpha2beta1-targeted probe for microPET imaging of prostate cancer, (in eng). Eur J Nucl Med Mol Imaging. 2011;38(7):1313–22.

    CAS  Article  Google Scholar 

  11. 11.

    Gilbert TM, et al. Neuroepigenetic signatures of age and sex in the living human brain. Nat Commun. 2019;10(1):2945.

    Article  Google Scholar 

  12. 12.

    Gilbert TM, et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest. 2019;129(1):364–72.

    Article  Google Scholar 

  13. 13.

    Wey HY, et al. Insights into neuroepigenetics through human histone deacetylase PET imaging. Sci Transl Med. 2016;8(351):351ra106.

    Article  Google Scholar 

  14. 14.

    Vaisanen S, Dunlop TW, Sinkkonen L, Frank C, Carlberg C. Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. J Mol Biol. 2005;350(1):65–77.

    CAS  Article  Google Scholar 

  15. 15.

    Li X, et al. Class I HDAC inhibitors display different antitumor mechanism in leukemia and prostatic cancer cells depending on their p53 status, (in eng). J Med Chem. 2018;61(6):2589–603.

    CAS  Article  Google Scholar 

  16. 16.

    Hu WY, et al. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate. 2019;79(10):1166–79.

    CAS  Article  Google Scholar 

  17. 17.

    Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer, (in eng). Pharmacol Ther. 2013;140(3):223–38.

    CAS  Article  Google Scholar 

  18. 18.

    Oh ET, et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells, (in eng). Investig New Drugs. 2012;30(2):435–42.

    CAS  Article  Google Scholar 

  19. 19.

    Denmeade SR, Isaacs JT. A history of prostate cancer treatment, (in eng). Nat Rev Cancer. 2002;2(5):389–96.

    CAS  Article  Google Scholar 

  20. 20.

    Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941, (in eng). J Urol. 2002;168(1):9–12.

    Article  Google Scholar 

  21. 21.

    Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41–5.

    CAS  Article  Google Scholar 

  22. 22.

    Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.

    CAS  Article  Google Scholar 

  23. 23.

    Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, (in eng). Future Med Chem. 2012;4(4):505–24.

    CAS  Article  Google Scholar 

  24. 24.

    McLeod AB, Stice JP, Wardell SE, Alley HM, Chang CY, McDonnell DP. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer, (in eng). Prostate. 2018;78(4):266–77.

    CAS  Article  Google Scholar 

  25. 25.

    Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose, (in eng). J Urol. 1996;155(3):994–8.

    CAS  Article  Google Scholar 

  26. 26.

    Oyama N, et al. The increased accumulation of [18F] fluorodeoxyglucose in untreated prostate cancer, (in eng). Jpn J Clin Oncol. 1999;29(12):623–9.

    CAS  Article  Google Scholar 

  27. 27.

    Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose, (in eng). Radiology. 1996;199(3):751–6.

    CAS  Article  Google Scholar 

  28. 28.

    Park SE, et al. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer. Investig New Drugs. 2018;36(2):195–205.

    CAS  Article  Google Scholar 

  29. 29.

    Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307(5707):269–73.

    CAS  Article  Google Scholar 

  30. 30.

    West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment, (in eng). J Clin Invest. 2014;124(1):30–9.

    CAS  Article  Google Scholar 

  31. 31.

    Munster PN, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker, (in eng). Br J Cancer. 2009;101(7):1044–50.

    CAS  Article  Google Scholar 

  32. 32.

    Wheler JJ, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers, (in eng). Cancer Chemother Pharmacol. 2014;73(3):495–501.

    CAS  Article  Google Scholar 

  33. 33.

    Jang YG, Hwang KA, Choi KC. Rosmarinic acid, a component of rosemary tea, induced the cell cycle arrest and apoptosis through modulation of HDAC2 expression in prostate cancer cell lines, (in eng). Nutrients. 2018;10(11):1784.

    Article  Google Scholar 

  34. 34.

    Meek DW. Tumour suppression by p53: a role for the DNA damage response?, (in eng). Nat Rev Cancer. 2009;9(10):714–23.

    CAS  Article  Google Scholar 

  35. 35.

    Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes, (in eng). Nat Rev Mol Cell Biol. 2008;9(5):402–12.

    CAS  Article  Google Scholar 

  36. 36.

    el-Deiry WS, et al. WAF1, a potential mediator of p53 tumor suppression, (in eng). Cell. 1993;75(4):817–25.

    CAS  Article  Google Scholar 

Download references


This work was supported by a pilot funding from the Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (C.W.), and a short-term visiting program of Sichuan University (Z.C.). The authors are grateful to the Athinoula A. Martinos Center Radiopharmacy Lab staff for the assistant in radiochemistry. The authors thank Drs. Jianzhong Ai, Kunjie Wang and Liang Zhou for their helpful discussion during the paper preparation and revision.

Author information




C.W. and Z.C. conceived the experiment. C.W., Y.Y., Z.C., X.W., H.W., X.Y., J.Y., T.L., D.R., R.K., C.R. performed research. C. W., X.Y., P.B., T. L., G.Y. analyzed data. C.W., Z.C., X.Y. wrote the paper. C.W., H.C., S.F., R.S., Q.C., H.L., B.X. contributed to writing and revising the manuscript. All authors read, revised if needed and approved the manuscript.

Corresponding authors

Correspondence to Hong Li or Changning Wang.

Ethics declarations

Competing interests

Dr. Changing Wang is a co-inventor of CN133 and [11C] Martinostat used in the paper. The other authors declare that they have no conflict of interest.

Ethical approval

The animal study was reviewed and approved by IACUC committee at Massachusetts General Hospital.

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology - General

Electronic supplementary material


(DOCX 364 kb).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, Z., Wang, X., Yang, X. et al. Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 48, 53–66 (2021).

Download citation


  • PET
  • HDAC
  • Epigenetics
  • CRPC